Results 231 to 240 of about 117,385 (313)
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin +11 more
wiley +1 more source
A bandgap‐engineered PtxTey:Ag2Te quantum dot platform enables tunable NIR‐IIb emission for deep‐tissue imaging and mild photothermal therapy. Conjugation with αPD‐L1 confers dual tumor targeting and real‐time monitoring of PD‐L1 dynamics. Mild photothermal modulation induces immune reprogramming, enhancing checkpoint blockade efficacy and achieving ...
Jing Liu +9 more
wiley +1 more source
This study establishes a CT‐based radiomics framework to quantify intratumoral heterogeneity (ITH) in HNSCC. Using unsupervised clustering, tumor ROIs and VOIs are analyzed to calculate 2D/3D ITH scores. The score shows strong predictive value for prognosis and immunotherapy response, and is associated with tumor metabolism and immune microenvironment,
Xinwei Chen +15 more
wiley +1 more source
Implementation of High Dose-rate Brachytherapy for Cervix Cancer in a Low-income Country. [PDF]
Nurkic SR +12 more
europepmc +1 more source
SLC25A13 is identified as an immunometabolic driver of triple‐negative breast cancer that sustains ferroptosis resistance and immune evasion through a STAT3–IFI6 circuit. Pharmacologic degradation of SLC25A13 restores ferroptosis sensitivity and enhances anti‐PD‐1 efficacy, highlighting a strategy to convert immune‐cold tumors into immunotherapy ...
Yingze Zhu +8 more
wiley +1 more source
MiR‐940 Suppresses Ferroptosis by Controlling Expression of Key Regulatory Genes
A CRISPR‐based screening identified miR‐940 as a critical suppressor of ferroptosis in cancer. By coordinating the downregulation of pro‐ferroptotic genes with the upregulation of GPX4, miR‐940 establishes a regulatory network that protects against ferroptosis and correlates with poor clinical outcomes in distinct cancer entities.
Andrea Kolak +19 more
wiley +1 more source
In vivo dosimetry of the rectum in image-guided adaptive interstitial-intracavitary brachytherapy of cervix cancer - A feasibility study. [PDF]
Fröhlich G +3 more
europepmc +1 more source
Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu +6 more
wiley +1 more source
SMAD4 is identified as a guardian of 3D genome architecture in lung squamous cell carcinoma. Loss of SMAD4 unleashes EP300 at chromatin loop anchors, strengthening enhancer–promoter looping and H3K27ac at the SOX2 locus to drive aberrant SOX2 activation and tumor cell proliferation.
Qian Tang +33 more
wiley +1 more source
Radioresistance severely limits the efficacy of therapies for small cell lung cancer (SCLC). This study reveals a novel mechanism of resistance driven by the active suppression of pyroptosis. Specifically, the mTORC2 complex directly phosphorylates GSDME‐N and promotes its CUL4B‐mediated ubiquitination and proteasomal degradation.
Qing‐qing Xu +11 more
wiley +1 more source

